CDKN2A and head and neck squamous cell carcinoma: Specifically, the OS rate was 57.1% (8/14) in the group with discordant HPV DNA and p16 IHC results, compared to 40% (3/5) in the group with discordant HPV E7 mRNA and p16 IHC results, indicating the prognostic disadvantage for patients with discordant categories and the advantages for incorporating the molecular mRNA profiling by QG-MPH to p16 IHC in making therapeutic decision and predicting patient outcomes in HNSCC.